fbpx

ENG

About Us

Home > For Medical Professionals / Oncology > Breast Cancer

Resources
for medical professionals

Breast Cancer

Consensus Statement on the Use of OncotypeDX in Patients WithResected, Hormone Receptor Positive and HER2-Negative, EarlyBreast Cancer: An Update of the Criteria for Reflex Testing


Acknowledgments: Dario Trapani, MD, and Harold Burstein, MD, PhD, for their leadership in the consensus discussions and in writing of the statements. Synopsis The consensus statements for Reflex Testing of OncotypeDX at Dana-Farber Cancer Institute Clinical Question Consensus Statement Reflex testing Can OncotypeDX be implemented as a reflex test in patients beyond 65 years old? […]

22/10/2023

Adjuvant Olaparib for High-Risk, Early Breast Cancer in BRCA1/2 Pathogenic or Likely Pathogenic Variant Carriers: Implications for Clinical Practice


Acknowledgments: Stefania Morganti, MD, and Filipa Lynce, MD, for their leadership in the consensus discussions and in writing of the statements. Coordination and editorial support were performed by Mr. Scorzoni and Ms. Bak. Synopsis Clinical Question Consensus Statement Q1. What should be the initial recommended treatment strategy to gBRCAm patients who received neoadjuvant chemo-immunotherapy and […]

3/09/2023

Consensus Statement Regarding use of Adjuvant Abemaciclib in Patients with Early-Stage, Hormone-Receptor-Positive Breast Cancer


Based on the significant improvement in invasive-disease-free survival (iDFS) observed in the phase III monarchE trial12, on October 12, 2021 the US Food and Drug Administration (FDA) approved the use of abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of high-risk, node-positive, early-stage, hormone-receptor-positive (HR+), HER2-negative breast cancer with a Ki-67 score ≥20%, as determined by an FDA-approved test.

10/08/2023

Consensus Statement Regarding Use of Pembrolizumabin Patients With Early-Stage Triple-Negative Breast Cancer


Based on the significant improvement in event-free survival (EFS) reported in the phase III Keynote-522 (KN522) trial, on July 26, 2021 the U.S. Food and Drug Administration approved the use of pembrolizumab for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

3/08/2023

The role of genetic testing and risk stratification in breast cancer prevention and screening


Our understanding of breast cancer has notably evolved from the early ancient times when this malignancy was described as the “black bile containing crab like tumors” by Hippocrates 460 BCE. The advent of modern medicine revolutionized our approach to breast cancer diagnosis and treatment, and further progress was achieved over the past few decades. Our therapies have exponentially improved to match the complexities of this multifaceted malignancy.

29/09/2022

Diagnosis and surgical management of early stage breast cancer


Breast cancer has become the most commonly diagnosed cancer worldwide, surpassing lung cancer in 2021. While breast cancer mortality has decreased in high-income countries, it continues to be elevated in low-middle and low-income countries

28/09/2022

Breast Cancer Pharmacology


Breast cancer therapies encompass a wide array of medications from different drug classes depending on the cancer’s receptor status. The chapter below will broadly discuss evidence-based therapies for breast cancer including endocrine agents, targeted agents (both oral and intravenous), immunotherapies, and chemotherapies. Please refer to the National Comprehensive Cancer Network (NCCN) guidelines for the most up to date recommendations or specific citations from this chapter or the guidelines for clinical trial specific information.

26/09/2022

Breast Cancer


Breast cancer is the second most commonly diagnosed malignancy in the world, following lung cancer. Every year, nearly two million women across the globe are diagnosed with breast cancer. It is also the leading cause of cancer mortality in women in the world. Fortunately, with advances in screening and systemic therapies, breast cancer outcomes are improving.

7/10/2021